**Question or request:**
1. What approach should New Mexico take to serologic coronavirus antibody testing?
2. What are the appropriate uses of the testing?
3. Should NM seek to purchase serologic testing kits in bulk?

**Recommendation/s in bullet form:**
- At the present time, serologic testing has a defined role in the following settings only: subset of acutely ill patients; focused epidemiologic surveillance during the ongoing outbreak and post-outbreak in vulnerable populations; general epidemiologic surveillance; as an important tool in studying long-term outcomes in individuals with symptomatic and asymptomatic COVID-19 disease.
- Serologic testing should be diversified to multiple platforms and at the same time focused on high-throughput hospital and reference lab-based testing from reliable manufacturers (ex. DiaSorin, Abbott, Roche, Beckman Coulter, Siemens) who have received FDA Emergency Use Authorizations (EUA) for their tests.
- NM reference labs should independently evaluate test characteristics to ensure high sensitivity (positive in people with disease) and specificity (negative test in people without disease).
- FDA now requires commercially marketed serological tests to receive EUA to continue to market them.
  - Lateral flow point-of-care rapid testing kits available may have received an FDA EUA, however the MAT still has concerns about their performance and does not recommend use of these devices.
- The State of NM can assist state labs to procure testing kits at this time (given predictable multiple supply chain interruptions due to overwhelming demand for reagents). The Scientific Laboratory Division of the Department of Health (DOH) is in negotiation with Abbott to purchase serologic test reagents when they become available and receive an EUA from FDA.
- DOH should provide specific guidance as to the proper use of antibody tests to the provider community and the public (to be attached).

**Assessment:**

<table>
<thead>
<tr>
<th>Expected APPROPRIATE Uses of Antibody Test</th>
<th>Non-Value-Added Uses of Antibody Testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focused epidemiologic surveillance during the ongoing outbreak and post-outbreak in vulnerable/special populations/locations (estimated need = 5000 tests)</td>
<td>To determine who can return to work – limited by the fact that we do not yet know whether the presence of antibody following disease is an indication of cure or protection from subsequent infection</td>
</tr>
<tr>
<td>General epidemiologic surveillance (estimated need = 5000 tests)</td>
<td>To satisfy curiosity about “Did I have COVID?”</td>
</tr>
<tr>
<td>Limited use: subset of acutely ill patients, as a complement to nucleic acid amplification testing to increase the sensitivity of lab diagnosis [they could be used in a complementary manner – both obtained at the same time since both will take a while to come back] (estimated need = 500 tests)</td>
<td>To determine who does and does not need a vaccine – limited by the fact that the presence or absence of an antibody response may not enter population-level vaccination policy</td>
</tr>
<tr>
<td>To study long-term outcomes of individuals with both symptomatic and asymptomatic COVID-19 disease (estimated need = 500 tests)</td>
<td></td>
</tr>
</tbody>
</table>

- The MAT recommends these criteria for selecting an antibody test:
  - High sensitivity and, particularly specificity to maximize positive predictive value.
  - Ability to be run in a high-throughput environment (rapid tests are NOT recommended).
o Highest possible probability that positive AND negative tests results will be automatically reported to DOH (which is not the case for point-of-care testing).

o There is an established and reliable supply chain for necessary test reagents.

o Highly reliable manufacturer with a wide distribution of machines in New Mexico (Ex: DiaSorin, Abbott, Roche, Beckman Coulter, Siemens).

- Antibody testing can be IgM (positive within 5-7 days of initial symptoms) and/or IgG (positive within 10-21 days of initial symptoms). While IgM and IgG arise nearly simultaneously with SARS-CoV-2 infection, IgG antibody testing is preferred over IgM antibody testing in this context because it is likely to have a lower false positive rate but with comparable sensitivity for detection of acute infection.

- NM labs can quickly validate newer tests coming onto the market.

- Blood specimens should be tested in both reference labs AND hospital labs throughout the state.

- New Mexico’s use of antibody testing should be diversified to at least three manufacturers to avoid the effects of supply chain interruptions as demand increases, though it should be noted that demand was lower than anticipated in the early months of the SARS-CoV-2 pandemic.

### New Mexico’s Use of Antibody Testing

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Testing Equipment Model Name/#</th>
<th>Antibody Testing Methodology</th>
<th>Reagents Needed</th>
<th>Throughput (tests/day)*</th>
<th>Reference Labs with Equipment</th>
<th>Number of NM Hospitals with Equipment</th>
<th>Estimated Reagent Cost per Test*</th>
</tr>
</thead>
<tbody>
<tr>
<td>DiaSorin</td>
<td>Liaison XL</td>
<td>Automated serology platform</td>
<td>DiaSorin kits, $12 each</td>
<td>800</td>
<td>TriCore</td>
<td>1</td>
<td>$12</td>
</tr>
<tr>
<td>Abbott</td>
<td>i1000</td>
<td>Automated serology platform</td>
<td>Abbott kits, $6.50 each</td>
<td>900</td>
<td>SLD</td>
<td>0</td>
<td>$6.50</td>
</tr>
<tr>
<td>Roche</td>
<td>Cobas e411</td>
<td>Automated serology platform</td>
<td>Roche kits</td>
<td>600</td>
<td>TriCore</td>
<td>2</td>
<td>$2</td>
</tr>
<tr>
<td>Beckman Coulter</td>
<td>DxI800</td>
<td>Automated serology platform</td>
<td>Beckman kits</td>
<td>3,000</td>
<td>TriCore</td>
<td>1</td>
<td>$6</td>
</tr>
<tr>
<td>Siemens</td>
<td>Centaur XP</td>
<td>Automated serology platform</td>
<td>Siemens kits</td>
<td>300</td>
<td>TriCore</td>
<td>3</td>
<td>$3</td>
</tr>
</tbody>
</table>

*Reagent cost per test only. Does not include other costs (labor, overhead, etc.)

Throughput per day will depend on reagent availability and allocations. As of 06/10/2020 TriCore Reference Laboratory currently performs testing the DiaSorin Liaison but has also validated Roche and will validate Beckman Coulter by late-June.

It is important to have guidance for both providers and the public regarding the appropriate use of antibody testing. Guidance to providers has been created and is available on MAT website. Public guidance is near completion, and will be posted on MAT website.
Red flags and concerns:
- Unsolicited emails offering access to point-of-care, rapid COVID-19 antibody tests should be considered suspicious.
- It is not known whether antibodies to coronavirus (COVID-19) predict immunity to the disease. Some viral illnesses (e.g., mumps) can occur when antibodies are present.
- The duration of immunity for COVID-19 after infection is not known. Other viral respiratory illnesses and their related vaccine (e.g., influenza) may confer immunity for only one year, which is why annual influenza immunization is recommended or required.

Contributors:
- Steve Jenison, MD NRP (DOH)
- Douglas Clark, MD (TriCore)
- Mike Edwards, PhD (SLD)
- David Grenache, PhD (TriCore)
- Kathy Kunkel (DOH)
- Michael Landen (DOH Epi)
- Chad Smelser (DOH Epi)
- Daniel Sosin (DOH Epi)
- Norbert Topf, MD (PHS)

Resources/Reference:

Additional References:


Also See Attached
Temporal dynamics in viral shedding and transmissibility of COVID-19

Xi He1, Eric H. Y. Lau2,3, Peng Wu1, Xilong Deng1, Jian Wang1, Xinxin Hao2, Yiu Chung Lau2, Jessica Y. Wong2, Yujuan Guan3, Xinghua Tan1, Xiaoneng Mo1, Yanqing Chen1, Baolin Liao1, Weilie Chen1, Fengyu Hu1, Qing Zhang1, Mingqiu Zhong1, Yanrong Wu1, Lingzhai Zhao1, Fuchun Zhang3, Benjamin J. Cowling4,5, Fang Li4,6 and Gabriel M. Leung2,4

We report temporal patterns of viral shedding in 94 patients with laboratory-confirmed COVID-19 and modeled COVID-19 infectiousness profiles from a separate sample of 77 infected-infector transmission pairs. We observed the highest viral load in throat swabs at the time of symptom onset, and inferred that infectiousness peaked on or before symptom onset. We estimated that 44% (95% confidence interval, 25–69%) of secondary cases were infected during the index cases’ presymptomatic stage, in settings with substantial household clustering, active case finding and quarantine outside the home. Disease control measures should be adjusted to account for probable substantial presymptomatic transmission.

SARS-CoV-2, the causative agent of COVID-19, spreads efficiently, with a basic reproductive number of 2.2 to 2.5 determined in Wuhan1,2. The effectiveness of control measures depends on several key epidemiological parameters (Fig. 1a), including the serial interval (duration between symptom onsets of successive cases in a transmission chain) and the incubation period (time between infection and onset of symptoms). Variation between individuals and transmission chains is summarized by the incubation period distribution and the serial interval distribution, respectively. If the observed mean serial interval is shorter than the observed mean incubation period, this indicates that a significant portion of transmission may have occurred before infected persons have developed symptoms. Significant presymptomatic transmission would probably reduce the effectiveness of control measures that are initiated by symptom onset, such as isolation, contact tracing and enhanced hygiene or use of face masks for symptomatic persons.

SARS (severe acute respiratory syndrome) was notable, because infectiousness increased around 7–10 days after symptom onset2,3. Onward transmission can be substantially reduced by containment measures such as isolation and quarantine (Fig. 1a)2. Thus, both transmission and the incubation period gradually decreases pattern.

In this study, we compared clinical data on virus shedding with separate epidemiologic data on incubation periods and serial intervals between cases in transmission chains, to draw inferences on infectiousness profiles.

Among 94 patients with laboratory-confirmed COVID-19 admitted to Guangzhou Eighth People’s Hospital, 47 (50%) were male, the median age was 47 years and 61 (66%) were moderately ill (with fever and/or respiratory symptoms and radiographic evidence of pneumonia), but none were classified as ‘severe’ or ‘critical’ on hospital admission (Supplementary Table 1).

A total of 414 throat swabs were collected from these 94 patients, from symptom onset up to 32 days after onset. We detected high viral loads soon after symptom onset, which then gradually decreased towards the detection limit at about day 21. There was no obvious difference in viral loads across sex, age groups and disease severity (Fig. 2).

Separately, based on 77 transmission pairs obtained from publicly available sources within and outside mainland China (Fig. 1b and Supplementary Table 2), the serial interval was estimated to have a mean of 5.8 days (95% confidence interval, 4.8–6.8 days) and a median of 5.2 days (95% CI, 4.1–6.3 days) based on a fitted gamma distribution, with 7.6% negative serial intervals (Fig. 1c). Assuming an incubation period distribution of mean 5.2 days from a separate study of early COVID-19 cases3, we inferred that infectiousness started from 2.3 days (95% CI, 0.8–3.0 days) before symptom onset and peaked at 0.7 days (95% CI, −0.2–2.0 days) before symptom onset (Fig. 1c). The estimated proportion of presymptomatic transmission (area under the curve) was 44% (95% CI, 25–69%). Infectiousness was estimated to decline quickly within 7 days. Viral load data were not used in the estimation but showed a similar monotonic decreasing pattern.

In sensitivity analysis, using the same estimating procedure but holding constant the start of infectiousness from 1 to 7 days before symptom onset, infectiousness was seen to peak at 0–2 days before symptom onset, and the proportion of presymptomatic transmission ranged from 46% to 55% (Extended Data Fig. 1).

Finally, simulation showed that the proportion of short serial intervals (for example, <2 days) would be larger if infectiousness were assumed to start before symptom onset (Extended Data Fig. 2). Given the 7.6% negative serial intervals estimated from the infected-infector paired data, start of infectiousness at least 2 days before onset and peak infectiousness at 2 days before to 1 day after onset would be most consistent with this observed proportion (Extended Data Fig. 3).

Here, we used detailed information on the timing of symptom onsets in transmission pairs to infer the infectiousness profile of COVID-19. We showed substantial transmission potential before symptom onset. Of note, most cases were isolated after symptom onset, preventing some post-symptomatic transmission.

1Guangzhou Eighth People’s Hospital, Guangzhou Medical University, Guangzhou, China. 2World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, University of Hong Kong, Hong Kong, SAR, China. 3These authors contributed equally: Xi He, Eric H. Y. Lau. 4These authors jointly supervised this work: Benjamin J. Cowling, Fang Li, Gabriel M. Leung. E-mail: e.y.lau@hku.hk.